Influence of amiodaroni on the diastolic function of the left ventricular myocardium in hypertension disease and the paroxysmal form of аtrial fibrillation
Abstract
The aim of this work. To evaluate the effect of amiodarone on the indicators of diastolic function of left ventricle in hypertensive disease (HD), complicated by paroxysmal atrial fibrillation (AF). Materials and methods. The study involved 99 patients with GB, complicated by paroxysmal and chronic AF. All patients underwent echocardiography (Echo) with determination of a set of common morphological and functional parameters. All patients were divided into 2 groups according to age characteristics: 41-60 years, and older than 60 years. When included in the studies all the patiens received amiodarone 600 mg IV to restore rhythm, later after rhythm restoration - in a dose of 150-450 mg per day during the year of observation. Results and conclusions. During the year of observation amiodarone had no effect on indices of diastolic function of the left ventricle (LV) with initial normal values in hypertension complicated with paroxysmal form of atrial brillation in patients aged 41-60 and older than 60 years. Amiodarone does not adversely affect the indicators of diastolic LV function in its initial disturbance according to the first type.
References
1. Коваль С.Н., Масляева Л.В., Резник Л.А. Взаимосвязь структурно-функциональных изменений сердца и уровня инсулиноподобного фактора роста 1 у больных гипертонической болезнью в сочетании с сахарным диабетом 2 типа // Внутрiшня Медицина. – 2009. – № 3. – С. 71–76.
2. Миллер О.Н., Тарасов А.В., Поздняков Ю.М., Лучинский С.А. Эффективность и влияние антиаритмической терапии на диастолическую функцию левого желудочка у пациентов сфибрилляцией предсердий // Российский кардиологический журнал. – 2011. – №4. – С. 56–67.
3. Татарский Б.А., Баталов Р.Е., Попов С.В. Фибрилляция предсердий: патофизиологические подходы к выбору антиаритмической терапии. – Томск: STT, 2013. – 483 с.
4. Bajpai A., Savelieva I., Camm J. Treatment of atrial fibrillation // Br. Med. Bull. –2008. – Vol. 88. – P. 75–94.
5. Cosio F.G., Aliot E., Botto G.L., et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode // Europace. – 2008. – Vol. 10 (1). – Р. 21–27. – DOI: https://doi.org/10.1093/europace/eum 276
6. Melduni R.M., Cullen M.W. Role of Left Ventricular Diastolic Dysfunction in Predicting Atrial Fibrillation Recurrence after Successful Electrical Cardioversion // J Atr Fibrillation. – 2012. – Vol. 5 (4). – P. 87–94.
7. Silver M., Pick R., Brilla C., et all. Reactive and reparative fibrillar collagen remodeling in the hypertrophied fat left ventricle: two experimental models of myocardial fibrosis // Cardiovasc Res. –1990. – Vol. 24. – P. 741–747.
8. Van Gelder I.C., Haegeli L.M., Brandes A., et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation // Europace. – 2011. – Vol. 11 (13). – P. 1517–1525. – DOI: http://doi.org/10.1093/europace/eur192.
9. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. // European Heart Journal. – 2016. – Vol. 37. – P. 2893–2962.
REFERENCES
1. Koval S.N., Maslyaeva L.V., Resnick L.A. The relationship of structural and functional changes of the heart and the level of insulin-like growth factor 1 in patients with essential hypertension combined with diabetes mellitus type 2 // Wnetrza Medicine. – 2009. – No. 3. – P. 71-76. (in Russian)
2. Miller O.N., Tarasov A.V., Pozdnyakov Y.M., Luchinsky S.A. Efficacy and effect of antiarrhythmic therapy on diastolic function of left ventricle in patients with atrial spirillaceae // Russian journal of cardiology. – 2011. – No 4. – P. 56-67.
3. Tatarskyi B. A., Batalov R.E., Popov S.N. Atrial fibrillation: pathophysiological approaches to the selection of antiarrhythmic therapy. – Tomsk: STT, 2013. – 483 p.
4. Bajpai A., Savelieva I., Camm J. Treatment of atrial fibrillation // Br. Med. Bull. –2008. – Vol. 88. – P. 75–94.
5. Cosio F.G., Aliot E., Botto G.L., et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode // Europace. – 2008. – Vol. 10 (1). – Р. 21–27. – DOI: https://doi.org/10.1093/europace/eum 276
6. Melduni R.M., Cullen M.W. Role of Left Ventricular Diastolic Dysfunction in Predicting Atrial Fibrillation Recurrence after Successful Electrical Cardioversion // J Atr Fibrillation. – 2012. – Vol. 5 (4). – P. 87–94.
7. Silver M., Pick R., Brilla C., et all. Reactive and reparative fibrillar collagen remodeling in the hypertrophied fat left ventricle: two experimental models of myocardial fibrosis // Cardiovasc Res. –1990. – Vol. 24. – P. 741–747.
8. Van Gelder I.C., Haegeli L.M., Brandes A., et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation // Europace. – 2011. – Vol. 11 (13). – P. 1517–1525. – DOI: http://doi.org/10.1093/europace/eur192.
9. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. // European Heart Journal. – 2016. – Vol. 37. – P. 2893–2962.
2. Миллер О.Н., Тарасов А.В., Поздняков Ю.М., Лучинский С.А. Эффективность и влияние антиаритмической терапии на диастолическую функцию левого желудочка у пациентов сфибрилляцией предсердий // Российский кардиологический журнал. – 2011. – №4. – С. 56–67.
3. Татарский Б.А., Баталов Р.Е., Попов С.В. Фибрилляция предсердий: патофизиологические подходы к выбору антиаритмической терапии. – Томск: STT, 2013. – 483 с.
4. Bajpai A., Savelieva I., Camm J. Treatment of atrial fibrillation // Br. Med. Bull. –2008. – Vol. 88. – P. 75–94.
5. Cosio F.G., Aliot E., Botto G.L., et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode // Europace. – 2008. – Vol. 10 (1). – Р. 21–27. – DOI: https://doi.org/10.1093/europace/eum 276
6. Melduni R.M., Cullen M.W. Role of Left Ventricular Diastolic Dysfunction in Predicting Atrial Fibrillation Recurrence after Successful Electrical Cardioversion // J Atr Fibrillation. – 2012. – Vol. 5 (4). – P. 87–94.
7. Silver M., Pick R., Brilla C., et all. Reactive and reparative fibrillar collagen remodeling in the hypertrophied fat left ventricle: two experimental models of myocardial fibrosis // Cardiovasc Res. –1990. – Vol. 24. – P. 741–747.
8. Van Gelder I.C., Haegeli L.M., Brandes A., et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation // Europace. – 2011. – Vol. 11 (13). – P. 1517–1525. – DOI: http://doi.org/10.1093/europace/eur192.
9. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. // European Heart Journal. – 2016. – Vol. 37. – P. 2893–2962.
REFERENCES
1. Koval S.N., Maslyaeva L.V., Resnick L.A. The relationship of structural and functional changes of the heart and the level of insulin-like growth factor 1 in patients with essential hypertension combined with diabetes mellitus type 2 // Wnetrza Medicine. – 2009. – No. 3. – P. 71-76. (in Russian)
2. Miller O.N., Tarasov A.V., Pozdnyakov Y.M., Luchinsky S.A. Efficacy and effect of antiarrhythmic therapy on diastolic function of left ventricle in patients with atrial spirillaceae // Russian journal of cardiology. – 2011. – No 4. – P. 56-67.
3. Tatarskyi B. A., Batalov R.E., Popov S.N. Atrial fibrillation: pathophysiological approaches to the selection of antiarrhythmic therapy. – Tomsk: STT, 2013. – 483 p.
4. Bajpai A., Savelieva I., Camm J. Treatment of atrial fibrillation // Br. Med. Bull. –2008. – Vol. 88. – P. 75–94.
5. Cosio F.G., Aliot E., Botto G.L., et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode // Europace. – 2008. – Vol. 10 (1). – Р. 21–27. – DOI: https://doi.org/10.1093/europace/eum 276
6. Melduni R.M., Cullen M.W. Role of Left Ventricular Diastolic Dysfunction in Predicting Atrial Fibrillation Recurrence after Successful Electrical Cardioversion // J Atr Fibrillation. – 2012. – Vol. 5 (4). – P. 87–94.
7. Silver M., Pick R., Brilla C., et all. Reactive and reparative fibrillar collagen remodeling in the hypertrophied fat left ventricle: two experimental models of myocardial fibrosis // Cardiovasc Res. –1990. – Vol. 24. – P. 741–747.
8. Van Gelder I.C., Haegeli L.M., Brandes A., et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation // Europace. – 2011. – Vol. 11 (13). – P. 1517–1525. – DOI: http://doi.org/10.1093/europace/eur192.
9. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. // European Heart Journal. – 2016. – Vol. 37. – P. 2893–2962.
Published
2018-06-05
How to Cite
ДИК, Ирина Сергеевна et al.
Influence of amiodaroni on the diastolic function of the left ventricular myocardium in hypertension disease and the paroxysmal form of аtrial fibrillation.
Sibirskij Medicinskij Zurnal (Irkutsk) = Siberian Medical Journal (Irkutsk) 16+, [S.l.], v. 151, n. 4, p. 17-20, june 2018.
ISSN 1815-7572. Available at: <http://smj.ismu.baikal.ru/index.php/osn/article/view/253>. Date accessed: 26 july 2026.
Issue
Section
Original research
